OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
YATH59

Yatharth Hospital & Trauma Care Services Ltd

Healthcare Facilities & ServicesVerified

Yatharth Hospital & Trauma Care Services Ltd maintains a strong liquidity position, with a current ratio of 7.59, indicating a significant buffer of current assets over current liabilities. The company's liquidity_fpt score is high, supported by cash and equivalents of INR 1,126.96 million, which is a substantial portion of its total assets. This liquidity position is further reinforced by a low debt-to-equity ratio of 0.1, suggesting minimal reliance on debt financing. In terms of profitability, the company's return on equity (ROE) of 4.39% and return on assets (ROA) of 3.76% are below the industry median for healthcare facilities and services, indicating that the company is not generating returns as efficiently as its peers. The net income of INR 383.48 million on a revenue of INR 1,779.67 million suggests a net margin of approximately 21.5%, which is relatively strong but not exceptional within the industry. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to regional economic or regulatory risks, although the current risk assessment does not flag this as a high concern. Looking ahead, the company is projected to experience moderate growth, with revenue expected to increase in the current fiscal year and the following year. The operating cash flow of INR -30.78 million and capital expenditure of INR -933.65 million indicate that the company is investing in its operations, which could support future growth. However, the negative operating cash flow suggests that the company is currently spending more than it is generating from operations, which may require continued reliance on financing or asset sales. The risk assessment indicates a low probability of dilution and no immediate liquidity concerns. The company's capital structure is stable, with a low debt-to-equity ratio and a strong equity base of INR 8,743.23 million. The absence of dilution flags and the low dilution risk suggest that the company is not expected to issue additional shares in the near term, preserving shareholder value. Recent filings and transcripts do not indicate any material events that would significantly impact the company's operations or financial position. The company's management has not disclosed any major strategic shifts or regulatory challenges in the latest reports. Analysts have assigned a mean recommendation of 2.00, indicating a "buy" rating, with a mean price target of INR 910.00, suggesting a positive outlook from the investment community.

30-day price · YATH+148.95 (+22.3%)
Low$630.90High$887.85Close$815.60As of15 May, 00:00 UTC
Profile
CompanyYatharth Hospital & Trauma Care Services Ltd
TickerYATH.NS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Yatharth Hospital & Trauma Care Services Ltd operates in the healthcare facilities and services industry, providing hospital and trauma care services to patients, generating revenue primarily through inpatient and outpatient care.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.

Yatharth Hospital & Trauma Care Services Ltd maintains a strong liquidity position, with a current ratio of 7.59, indicating a significant buffer of current assets over current liabilities. The company's liquidity_fpt score is high, supported by cash and equivalents of INR 1,126.96 million, which is a substantial portion of its total assets. This liquidity position is further reinforced by a low debt-to-equity ratio of 0.1, suggesting minimal reliance on debt financing. In terms of profitability, the company's return on equity (ROE) of 4.39% and return on assets (ROA) of 3.76% are below the industry median for healthcare facilities and services, indicating that the company is not generating returns as efficiently as its peers. The net income of INR 383.48 million on a revenue of INR 1,779.67 million suggests a net margin of approximately 21.5%, which is relatively strong but not exceptional within the industry. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to regional economic or regulatory risks, although the current risk assessment does not flag this as a high concern. Looking ahead, the company is projected to experience moderate growth, with revenue expected to increase in the current fiscal year and the following year. The operating cash flow of INR -30.78 million and capital expenditure of INR -933.65 million indicate that the company is investing in its operations, which could support future growth. However, the negative operating cash flow suggests that the company is currently spending more than it is generating from operations, which may require continued reliance on financing or asset sales. The risk assessment indicates a low probability of dilution and no immediate liquidity concerns. The company's capital structure is stable, with a low debt-to-equity ratio and a strong equity base of INR 8,743.23 million. The absence of dilution flags and the low dilution risk suggest that the company is not expected to issue additional shares in the near term, preserving shareholder value. Recent filings and transcripts do not indicate any material events that would significantly impact the company's operations or financial position. The company's management has not disclosed any major strategic shifts or regulatory challenges in the latest reports. Analysts have assigned a mean recommendation of 2.00, indicating a "buy" rating, with a mean price target of INR 910.00, suggesting a positive outlook from the investment community.
Key takeaways
  • Yatharth Hospital & Trauma Care Services Ltd has a strong liquidity position with a current ratio of 7.59 and a low debt-to-equity ratio of 0.1.
  • The company's profitability metrics, including ROE of 4.39% and ROA of 3.76%, are below the industry median, indicating room for improvement in operational efficiency.
  • The company's revenue is concentrated in a single business segment, with no significant geographic diversification reported.
  • Analysts have assigned a "buy" rating to the stock, with a mean price target of INR 910.00, reflecting a positive outlook.
  • The company is investing in its operations, with a capital expenditure of INR -933.65 million, which may support future growth.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$1.78B
Gross profit$1.40B
Operating income$1.01B
Net income$383.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$30.8M
CapEx-$933.6M
Free cash flow
Total assets$10.19B
Total liabilities$1.45B
Total equity$8.74B
Cash & equivalents$1.13B
Long-term debt$846.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$2.29B$506.8M$181.6M$200.1M
FY-3$4.01B$941.1M$441.6M$589.0M
FY-2$5.20B$1.19B$657.7M$734.6M
FY-1$6.71B$1.71B$1.14B$504.1M
FY0$8.80B$2.02B$1.31B-$1.23B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$3.09B$724.5M$50.0M
FY-3$4.26B$1.17B$117.1M
FY-2$4.86B$1.83B$374.3M
FY-1$10.19B$8.74B$1.13B
FY0$17.47B$16.05B$3.62B
PeriodOCFCapExFCFSBC
FY-4$436.7M-$201.3M$200.1M
FY-3$600.1M-$131.3M$589.0M
FY-2$637.8M-$198.1M$734.6M
FY-1-$30.8M-$933.6M$504.1M
FY0$1.50B-$3.11B-$1.23B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$1.78B$1.01B$383.5M
FQ-6$2.12B$1.19B$303.8M
FQ-5$2.18B$1.17B$309.5M
FQ-4$2.19B$1.18B$304.9M
FQ-3$2.32B$1.29B$387.2M
FQ-2$2.58B$1.41B$420.4M
FQ-1$2.79B$1.50B$412.4M
FQ0$3.20B$502.9M$453.5M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$10.19B$8.74B$1.13B
FQ-6
FQ-5$10.93B$9.32B$1.56B
FQ-4
FQ-3$17.47B$16.05B$3.62B
FQ-2
FQ-1$18.56B$16.89B$1.73B
FQ0
PeriodOCFCapExFCFSBC
FQ-7-$30.8M-$933.6M
FQ-6
FQ-5$703.5M-$823.2M
FQ-4
FQ-3$1.50B-$3.11B
FQ-2
FQ-1$485.1M-$1.97B
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$8.74B
Net cash$280.5M
Current ratio7.6
Debt/Equity0.1
ROA3.8%
ROE4.4%
Cash conversion-8.0%
CapEx/Revenue-52.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricYATHActivity
Op margin56.6%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin21.5%5.9% medp25 -3.8% · p75 12.8%top quartile
Gross margin78.8%45.5% medp25 31.1% · p75 62.9%top quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-52.5%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity10.0%25.0% medp25 3.8% · p75 63.3%below median
Observations
IR observations
Mean price target910.00 INR
Median price target910.00 INR
High price target920.00 INR
Low price target900.00 INR
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate17.45 INR
Last actual EPS14.72 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 00:43 UTC#0ccd7c9c
Source: analysis-pipeline (hybrid)Generated: 2026-05-30 02:28 UTCJob: 22c7f262